103,144 Shares in Insmed, Inc. $INSM Acquired by Nykredit A S

Key Points

• Nykredit A S acquired 103,144 Insmed shares during the second quarter, valued at approximately $11.0 million, adding to broader institutional interest in the biopharmaceutical company.
• Insmed reported quarterly revenue of $425.5 million, up 296.1% year over year, and posted an adjusted loss of $0.06 per share—beating analysts’ expected loss of $0.67. The stock opened at $126.29, well below its 52-week high of $212.75.
• Analysts maintain a favorable outlook, with a consensus “Buy” rating and an average price target of $205.52, although company insiders sold 273,753 shares worth $35.6 million during the latest quarter.

Nykredit A S purchased a new position in Insmed, Inc. (NASDAQ:INSM - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 103,144 shares of the biopharmaceutical company's stock, valued at approximately $10,997,000.

Other large investors also recently added to or reduced their stakes in the company. Reflection Asset Management purchased a new stake in Insmed in the fourth quarter worth $30,000. CIBC Private Wealth Group LLC boosted its stake in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 53 shares during the period. Raiffeisen Bank International AG bought a new stake in Insmed in the 4th quarter worth approximately $32,000. Larson Financial Group LLC increased its stake in Insmed by 137.0% during the fourth quarter. Larson Financial Group LLC now owns 256 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 148 shares during the last quarter. Finally, Towarzystwo Funduszy Inwestycyjnych PZU SA purchased a new stake in shares of Insmed in the fourth quarter valued at $49,000.

Insmed Stock Performance

Shares of INSM stock opened at $126.29 on Friday. Insmed, Inc. has a 52-week low of $90.39 and a 52-week high of $212.75. The stock has a market capitalization of $27.58 billion, a PE ratio of -30.73 and a beta of 0.82. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74. The stock's 50-day moving average price is $115.86 and its 200 day moving average price is $125.22.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The firm had revenue of $425.49 million during the quarter, compared to the consensus estimate of $395.50 million. During the same quarter last year, the firm earned ($1.70) earnings per share. The firm's revenue was up 296.1% compared to the same quarter last year. As a group, equities research analysts forecast that Insmed, Inc. will post -1.83 EPS for the current year.

Insider Activity at Insmed

In other news, COO Roger Adsett sold 239,850 shares of the business's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the sale, the chief operating officer owned 98,744 shares in the company, valued at approximately $13,159,612.88. The trade was a 70.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 10,699 shares of the company's stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $117.40, for a total value of $1,256,062.60. Following the completion of the sale, the chief executive officer directly owned 259,058 shares of the company's stock, valued at $30,413,409.20. The trade was a 3.97% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 273,753 shares of company stock valued at $35,604,764 over the last quarter. Insiders own 2.10% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on INSM. Wells Fargo & Company boosted their price objective on shares of Insmed from $161.00 to $169.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Royal Bank Of Canada cut their price objective on Insmed from $205.00 to $195.00 and set an "outperform" rating for the company in a research report on Friday, June 5th. BMO Capital Markets started coverage on shares of Insmed in a research note on Monday, July 20th. They issued an "outperform" rating and a $192.00 price target on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $235.00 price target on shares of Insmed in a research report on Tuesday, July 28th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Insmed in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $205.52.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source